Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
- Conditions
- HIV InfectionsChickenpox
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-01
- Target Recruit Count
- 180
- Registration Number
- NCT00000953
- Locations
- 🇺🇸
Med College of Georgia, Augusta, Georgia, United States
🇺🇸UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Veterans Administration Med Ctr, Martinez, California, United States
A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 57
- Registration Number
- NCT00001021
- Locations
- 🇺🇸
Vanderbilt Univ Hosp, Nashville, Tennessee, United States
🇺🇸St Louis Univ School of Medicine, St Louis, Missouri, United States
🇺🇸Univ of Rochester Med Ctr, Rochester, New York, United States
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001091
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸State Univ of New York at Stony Brook, Stony Brook, New York, United States
🇺🇸Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 140
- Registration Number
- NCT00001072
- Locations
- 🇺🇸
JHU AVEG, Baltimore, Maryland, United States
🇺🇸Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸UAB AVEG, Birmingham, Alabama, United States
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
- Conditions
- HIV InfectionsStomatitis, Aphthous
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 164
- Registration Number
- NCT00000790
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Louis A Weiss Memorial Hosp, Chicago, Illinois, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 654
- Registration Number
- NCT00001029
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 230
- Registration Number
- NCT00000789
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States
🇺🇸St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1750
- Registration Number
- NCT00000841
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000968
- Locations
- 🇺🇸
St. Louis Univ. School of Medicine AVEG, Saint Louis, Missouri, United States
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 56
- Registration Number
- NCT00000746
- Locations
- 🇺🇸
JHU AVEG, Pittsburgh, Pennsylvania, United States